ClouDr Group Limited (HK:9955)
:9955
Want to see HK:9955 full AI Analyst Report?
Top Page
ClouDr Group Limited
(9955)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.73
▼(-26.70% Downside)
Action:Upgraded
Date:05/12/26
The score is held down primarily by weak financial performance—sharp 2025 revenue contraction and persistent large net losses, with free cash flow still negative despite improved operating cash flow. Technicals provide a modest offset with improving short-term momentum, but the longer-term trend remains below key moving averages. Valuation is also a headwind due to negative earnings (negative P/E) and no indicated dividend yield.
Positive Factors
Omnichannel retail footprint
ClouDr's combined offline and online pharmacy network provides durable distribution breadth and customer access across channels. That multichannel presence supports steady prescription flow, cross-selling and resilience to single-channel disruption, helping sustain revenues and unit economics over months.
Negative Factors
Sharp revenue contraction
A ~30% revenue decline materially reduces scale benefits and pressures unit economics. Loss of top-line momentum undermines bargaining power with suppliers, increases fixed-cost absorption needs, and makes margin recovery harder absent clear evidence of sustainable sales stabilization.
Read all positive and negative factors
Positive Factors
Negative Factors
Omnichannel retail footprint
ClouDr's combined offline and online pharmacy network provides durable distribution breadth and customer access across channels. That multichannel presence supports steady prescription flow, cross-selling and resilience to single-channel disruption, helping sustain revenues and unit economics over months.
Read all positive factors
ClouDr Group Limited (9955) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$437.54M
Dividend YieldN/A
Average Volume (3M)1.09M
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue Growth-53.49%
EPS Growth-68.66%
CountryHK
Employees1,218
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-1.60
Shares Outstanding645,718,800
10 Day Avg. Volume899,970
30 Day Avg. Volume1,090,236
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.00
Price to Sales (P/S)0.35
P/FCF Ratio-8.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)HK$7.73B
ClouDr Group Limited Business Overview & Revenue Model
Company Description
ClouDr Group Limited, an investment holding company, provides supplies and software as a service (SaaS) to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions for chronic cond...
How the Company Makes Money
ClouDr Group Limited primarily makes money by selling healthcare-related products to consumers through its pharmacy retail network and associated online channels. Its key revenue stream is retail sales of medicines (including prescription drugs an...
ClouDr Group Limited Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.26B | 1.58B | 3.49B | 3.69B | 2.99B | 1.76B |
| Gross Profit | 755.69M | 755.02M | 861.67M | 909.38M | 792.10M | 570.02M |
| EBITDA | -764.00M | -498.71M | -372.34M | -208.37M | -1.58B | -4.06B |
| Net Income | -949.68M | -900.23M | -516.41M | -323.06M | -1.69B | -4.14B |
Balance Sheet | ||||||
| Total Assets | 2.15B | 1.68B | 2.84B | 2.95B | 2.83B | 2.51B |
| Cash, Cash Equivalents and Short-Term Investments | 445.29M | 449.77M | 525.84M | 595.10M | 723.17M | 1.12B |
| Total Debt | 558.23M | 288.75M | 581.24M | 469.69M | 228.67M | 9.03B |
| Total Liabilities | 1.33B | 1.20B | 1.41B | 1.18B | 953.05M | 9.66B |
| Stockholders Equity | 962.37M | 548.79M | 1.45B | 1.83B | 1.85B | -7.14B |
Cash Flow | ||||||
| Free Cash Flow | -24.36M | -65.22M | -225.19M | -263.46M | -809.87M | -755.02M |
| Operating Cash Flow | 61.47M | 82.38M | -148.39M | -140.43M | -642.63M | -666.33M |
| Investing Cash Flow | 40.20M | 9.33M | 66.87M | -38.34M | -744.94M | -155.50M |
| Financing Cash Flow | 7.56M | -32.72M | 147.99M | 171.81M | 503.55M | 1.02B |
ClouDr Group Limited Technical Analysis
Negative
1.00
Price Trends
0.74
Negative
0.89
Negative
1.12
Negative
Market Momentum
>-0.01
Negative
48.65
Neutral
53.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9955, the sentiment is Negative. The current price of 1 is above the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.74, and below the 200-day MA of 1.12, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.65 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9955.
ClouDr Group Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$6.11B | 9.08 | 6.83% | 2.72% | 15.04% | 5.57% | |
60 Neutral | HK$628.56M | 7.33 | 7.59% | 8.03% | -1.01% | -13.09% | |
57 Neutral | HK$55.80B | 3.75 | 8.62% | 3.75% | -1.57% | 1.55% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$437.54M | -0.61 | -66.54% | ― | -53.49% | -68.66% | |
42 Neutral | HK$1.43B | 112.06 | 1.09% | 3.81% | -10.71% | -87.93% | |
41 Neutral | HK$762.93M | -5.63 | 476.63% | ― | -17.39% | -45.76% |
* Healthcare Sector Average
HK:9955
ClouDr Group Limited
0.68
-0.39
-36.45%
HK:0673
China Health Group
0.55
0.44
400.00%
HK:1099
Sinopharm Group Co
17.88
-0.10
-0.56%
HK:1931
IVD Medical Holding Limited
0.88
-0.87
-49.71%
HK:2192
Medlive Technology Co., Ltd.
8.25
-3.52
-29.91%
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.82
-1.44
-19.83%
ClouDr Group Limited Corporate Events
ClouDr Group Delays AGM and Adjusts Share Register Closure
May 11, 2026
ClouDr Group Limited has postponed its annual general meeting, originally set for June 8, 2026, to a new date on or before June 30, 2026, citing adjustments to its business arrangements. The company will publish a new notice and circular specifyin...
ClouDr Group’s Revenue Halves in 2025 as Losses Deepen and Dividend Scrapped
Mar 26, 2026
ClouDr Group Limited reported a sharp deterioration in its 2025 financial performance, with revenue halving to RMB1.62 billion from RMB3.49 billion and gross profit falling 10%, reflecting steep declines across both in-hospital and out-of-hospital...
ClouDr Group Sets Board Meeting to Approve 2025 Annual Results
Mar 16, 2026
ClouDr Group Limited has scheduled a board meeting for March 26, 2026, to review and approve the annual results for the year ended December 31, 2025, and to authorize their publication. The meeting signals the company’s preparation to update...
ClouDr flags wider 2025 loss as AI-focused overhaul boosts cash flow
Feb 16, 2026
ClouDr Group Limited has warned that its consolidated net loss for the year ended December 31, 2025 is expected to widen to between RMB880 million and RMB980 million, compared with a RMB491.4 million loss a year earlier. The deterioration is mainl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.